(Q30475523)

4 November 2017

The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice (English)

1 reference

4 November 2017

4

1 reference

4 November 2017

Denis Boulay

1

1 reference

4 November 2017

Olivier Bergis

series ordinal

2

1 reference

4 November 2017

Patrick Avenet

series ordinal

3

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

4 November 2017

Neuropsychopharmacology

1 reference

4 November 2017

35

1 reference

4 November 2017

2

1 reference

4 November 2017

416-427

1 reference

Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice

4 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Glycine transporter inhibitors as therapeutic agents for schizophrenia.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

D-alanine added to antipsychotics for the treatment of schizophrenia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Glutamate receptor function in learning and memory

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Genetic animal models: focus on schizophrenia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

To model a psychiatric disorder in animals: schizophrenia as a reality test

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Mice with reduced NMDA receptor expression display behaviors related to schizophrenia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

The switching model of latent inhibition: an update of neural substrates

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Neurocircuitries and neurotransmitter interactions in schizophrenia.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Neurotransmitter transporters: recent progress

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

The current status of the dopamine hypothesis of schizophrenia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Positive and negative symptoms: historical and conceptual aspects

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055391

Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

20 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Repeated low dose of phencyclidine administration impairs spatial learning in mice: blockade by clozapine but not by haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Interactions between the glycine transporter 1(GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Cannabinoid pharmacological properties common to other centrally acting drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.144

Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice

21 January 2018

1 reference

12 December 2020

Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia

1 reference

12 December 2020

The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice

1 reference

12 December 2020

Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse

1 reference

12 December 2020

Identifiers

DOI

10.1038/NPP.2009.144

1 reference

Dimensions Publication ID

4 November 2017

0 references

1 reference

4 November 2017

PubMed publication ID

19759529

1 reference